Basiliximab

Basiliximab
Monoclonal antibody
Type	Whole antibody
Source	Chimeric (mouse/human)
Target	CD25
Clinical data
Trade names	Simulect
AHFS/Drugs.com	Monograph
License data	EU EMA: by INN;
Pregnancy; category	AU: D;
ATC code	L04AC02 (WHO) ;
Pharmacokinetic data
Elimination half-life	7.2 days
Identifiers
CAS Number	179045-86-4 ;
DrugBank	DB00074 ;
ChemSpider	none;
UNII	9927MT646M;
ChEMBL	ChEMBL1201439 ;
Chemical and physical data
Formula	C6378H9844N1698O1997S48
Molar mass	143801.68 g·mol−1
	(what is this?) (verify)

Basiliximab (trade name Simulect) is a chimeric mouse-human monoclonal antibody to the α chain (CD25) of the IL-2 receptor of T cells. It is used to prevent rejection in organ transplantation, especially in kidney transplants.

Uses

Basiliximab is an immunosuppressant agent used to prevent immediate transplant rejection in people who are receiving kidney transplants, in combination with other agents.[1] It has been reported that some cases of lichen planus have been successfully treated with basiliximab as an alternative therapy to cyclosporin. No short-term side effects have been reported.[2]

Mechanism of action

Basiliximab competes with IL-2 to bind to the alpha chain subunit of the IL2 receptor on the surface of the activated T lymphocytes and thus prevents the receptor from signaling. This prevents T cells from replicating and also from activating B cells, which are responsible for the production of antibodies, which would bind to the transplanted organ and stimulate an immune response against the transplant.[3][4]

Chemistry

It is a chimeric CD25 monoclonal antibody of the IgG1 isotype.[3][4]

History

It is a Novartis product and was approved by the Food and Drug Administration (FDA) in 1998.[5]

References and notes

MedlinePlus. Last Revised - June 15, 2012 Basiliximab Injection
Katsambas AD, Lotti TM (2003). European handbook of dermatological treatments (2nd ed.). p. 291. ISBN 3-540-00878-0.
Hardinger KL, Brennan DC, Klein CL (July 2013). "Selection of induction therapy in kidney transplantation". Transplant International. 26 (7): 662–72. doi:10.1111/tri.12043. PMID 23279211. S2CID 3296555.
Basiliximab label
Waldmann TA (March 2003). "Immunotherapy: past, present and future". Nature Medicine. 9 (3): 269–77. doi:10.1038/nm0303-269. PMID 12612576. S2CID 9745527.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[Medline-1] MedlinePlus. Last Revised - June 15, 2012 Basiliximab Injection

[2] Katsambas AD, Lotti TM (2003). European handbook of dermatological treatments (2nd ed.). p. 291. ISBN 3-540-00878-0.

[HardingerRev-3] Hardinger KL, Brennan DC, Klein CL (July 2013). "Selection of induction therapy in kidney transplantation". Transplant International. 26 (7): 662–72. doi:10.1111/tri.12043. PMID 23279211. S2CID 3296555.

[label-4] Basiliximab label

[pmid12612576-5] Waldmann TA (March 2003). "Immunotherapy: past, present and future". Nature Medicine. 9 (3): 269–77. doi:10.1038/nm0303-269. PMID 12612576. S2CID 9745527.